Navigation Links
Southampton scientists begin patient trials of new leukemia cancer vaccine
Date:1/31/2011

A new cancer treatment which strengthens a patient's immune system and enables them to fight the disease more effectively is being trialled on patients for the first time in the UK.

The treatment will use a new DNA vaccine, developed by scientists from the University of Southampton, which will treat a selected group of volunteers who have either chronic or acute myeloid leukaemia - two forms of bone marrow and blood cancer.

Scientists believe they can control the disease by vaccinating patients against a cancer-associated gene (Wilm's Tumour gene 1), found 'expressed' in almost all chronic and acute leukaemias.

A team of researchers and health practitioners, led by Professor Christian Ottensmeier of the University of Southampton Experimental Cancer Medicine Centre and Dr Katy Rezvani of Imperial College London and Imperial College Healthcare NHS Trust, hope to recruit up to 180 patients to the trial which will take place at hospitals in Southampton, London and Exeter over the next two years.

The research is funded by the charity Leukaemia & Lymphoma Research and the Efficacy and Mechanism Evaluation (EME) programme, which is financed by the Medical Research Council (MRC) and managed by the National Institute for Health Research (NIHR).

"In chronic myeloid leukaemia, current treatment can reduce the cancer but the drug needs to be taken indefinitely and has unpleasant side effects. Prognosis of acute myeloid leukaemia is currently poor and better treatments are urgently needed," comments Christian Ottensmeier, professor of experimental cancer medicine at the University of Southampton and consultant oncologist at Southampton University Hospitals NHS Trust.

"We have already demonstrated that this new type of DNA vaccine is safe and can successfully activate the immune systems in patients with cancer of the prostate, bowel and lung. We believe it will prove to be beneficial to patients with acute and chronic
'/>"/>

Contact: Sophie Docker
S.Docker@soton.ac.uk
44-238-059-8933
University of Southampton
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Southampton scientists begin Phase II patient trial for new asthma treatment
2. Southampton to conduct UKs first cochlear implant operation to give sound in both ears
3. Scientists Pinpoint Area of Brain That Fears Losing Money
4. Scientists Discover How HIV Is Transmitted Between Men
5. Prevention Is Key Research Goal for Premature Babies, Scientists Say
6. Scientists Discover Molecular Pathway for Organ Tissue Regeneration and Repair
7. Scientists find donut-shaped structure of enzyme involved in energy metabolism
8. Neuroscientists reveal new links that regulate brain electrical activity
9. Two UCSF Scientists to Receive Prestigious Dementia Research Honor
10. Johns Hopkins scientists develop personalized blood tests for cancer using whole genome sequencing
11. Scientists Spot Genetic Fingerprints of Individual Cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2014)... 23, 2014 Today Zane Benefits, ... small businesses, announced their new on demand webinar ... Employer-Provided Health Insurance. , According to ... financial risk facing most American families. It is ... and large, when it comes to recruiting and ...
(Date:11/22/2014)... Recently, UWDress.com, a successful wedding dress shop, has ... in order to prepare for the wedding season. All ... off. , UWDress.com is a reliable company that has ... the new items -- formal wedding guest attire. This new ... including superstar and princess. As one of the leading companies ...
(Date:11/22/2014)... NY (PRWEB) November 22, 2014 ... Goods Administration (TGA) approved it for use “as ... approved and listed within the Therapeutic Goods (Listing) ... , Kyowa Hakko’s Setria® Glutathione will be ... biotech specialist that sources and imports fine chemicals ...
(Date:11/22/2014)... November 22, 2014 "My friend went ... caused by the machine," said an inventor from Cambria ... to go back a second time because the first ... , She developed the patent-pending MAMO EASY to offer ... The design saves the patient from the pain normally ...
(Date:11/22/2014)... York (PRWEB) November 22, 2014 Lipitor ... behalf of patients who allegedly developed Type 2 diabetes ... the federal multidistrict litigation now underway in U.S. District ... According to court documents, the litigation will convene its ... The Court has directed Lead Counsel for Plaintiffs and ...
Breaking Medicine News(10 mins):Health News:Zane Benefits, Inc. Announces New Webinar on The End of Employer-Provided Health Insurance Now Available On-Demand! 2Health News:Formal Wedding Guest Attire Added to UWDress.com 2Health News:Setria® Glutathione Now Available in Australia 2Health News:Setria® Glutathione Now Available in Australia 3Health News:Lipitor Lawsuit Conference Scheduled for December, Bernstein Liebhard LLP Reports 2Health News:Lipitor Lawsuit Conference Scheduled for December, Bernstein Liebhard LLP Reports 3
... finds people who participated in a cardiac-rehab program after a ... as those of the same age and sex who had ... of the deaths that occurred among patients in their study ... ,The investigation involved about 1,800 patients. Nearly 60 percent ...
... low-glycemic index diet can lead to weight loss, reduced ... and cardiovascular disease. In low-GI foods, carbohydrates are low ... include white bread, refined breakfast cereals and concentrated sugars, ... to high levels. Carbs that release sugar more slowly ...
... A new study shows consuming foods or supplements containing the ... way to avoid Alzheimer’s disease // even if you carry ... the study researchers first bred mice to carry the gene ... Initially various environmental factors affecting the symptoms were studied but ...
... at an increased risk of dying from heart disease. ... more traits of metabolic syndrome have a 3.5-times higher ... syndrome is a group of metabolic risk factors including ... disorders, insulin resistance or glucose intolerance, and high-normal blood ...
... Mental decline usually associated with age, might affect women ... according to a recent study .// ,The ... worse cognitive performance and are at an increased risk ... cognitive impairment among women with pre-diabetes or diabetes was ...
... the number of Americans living with high blood pressure has ... pressure is defined // as having blood pressure of 140/90 ... their doctors at least twice that their blood pressure is ... ,However researchers say the study did not examine the reasons ...
Cached Medicine News:
(Date:11/21/2014)... N.J. , Nov. 21, 2014  PTC Therapeutics, Inc. ... the 2014 Legend of Technology Award for Vision, Innovation, and ... Ph.D., Chief Executive Officer. This award recognizes an individual who ... New Jersey for several decades. ... Technology Award," stated Stuart Peltz , Ph.D., CEO of ...
(Date:11/21/2014)... and MELVILLE, N.Y. , Nov. 21, ... ), one of the world,s largest health care services ... ), the world,s largest provider of health care products ... practitioners, today announced that the companies have entered into ... most comprehensive service and product offerings to office-based medical ...
(Date:11/21/2014)... 20, 2014 /PRNewswire/-- CANTEL MEDICAL CORP. (NYSE: CMN ) ... Officer, will be presenting at the 26 th Annual ... in New York . The formal presentation ... ET. In addition, Mr. Krakauer and Jorgen B. Hansen ... meetings during the day. An audio webcast ...
Breaking Medicine Technology:PTC Therapeutics Announces CEO, Dr. Stuart Peltz Recipient of The New Jersey Technology Council's 2014 Legend of Technology Award 2PTC Therapeutics Announces CEO, Dr. Stuart Peltz Recipient of The New Jersey Technology Council's 2014 Legend of Technology Award 3Cardinal Health And Henry Schein Enter Into Long-Term Strategic Agreement To Serve Physician Offices 2Cardinal Health And Henry Schein Enter Into Long-Term Strategic Agreement To Serve Physician Offices 3Cardinal Health And Henry Schein Enter Into Long-Term Strategic Agreement To Serve Physician Offices 4Cardinal Health And Henry Schein Enter Into Long-Term Strategic Agreement To Serve Physician Offices 5
... Johnson & Johnson Pharmaceutical,Research & Development, ... demonstrate doripenem (DORIBAX(TM), doripenem for injection), a,carbapenem ... in vitro against certain,strains of Enterobacteriaceae, including ... Enterobacteriaceae is a large group of ...
... annual ICAAC/IDSA meeting in Washington, D.C., WASHINGTON, ... nail,fungus, NB-002, has demonstrated a new topical approach ... diffusing through the skin that,surrounds the entire nail ... The data represent a unique approach to ...
Cached Medicine Technology:New Data Show In Vitro Potency of Doripenem Against Resistant Bacteria 2New Data Show In Vitro Potency of Doripenem Against Resistant Bacteria 3New Data Show In Vitro Potency of Doripenem Against Resistant Bacteria 4New Data Show In Vitro Potency of Doripenem Against Resistant Bacteria 5NanoBio Demonstrates New Topical Approach to Treating Nail Fungus That Circumvents Problems with Current Therapy 2NanoBio Demonstrates New Topical Approach to Treating Nail Fungus That Circumvents Problems with Current Therapy 3
The Gizmo male external catheter is a latex catheter that uses a single-sided adhesive strip....
... The Mentor Freedom Pak Seven ... packaged week's supply of Freedom ... kit all 100% latex-free ... wipes for your convenience and ...
Clear Advantage® is a premium 100% latex-free, self-adhering, one-piece catheter designed for maximum wear. It features aloe in the adhesive, and a kink-resistant nozzle designed to eliminate blo...
... all-silicone non-adhesive male external catheter is ... latex-related allergic reactions. It is designed ... change external catheters several times a ... catheter comes with an adjustable strap ...
Medicine Products: